Moderna stock has surged 663% in 2026, outpacing AI stocks to become the top performer on the S&P 500. This exceptional rally is driven in part by anticipation of full cancer vaccine data expected on October 24. The biotech success reflects growing investor interest in mRNA-based therapies.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
